Iovance Biotherapeutics (IOVA) had made a very large impact at ASCO 2019 and it was one of the clear winners for the medical conference. That's because it reported positive results from two of its studies. The positive results were made possible through the use of the biotech's Tumor infiltrating lymphocytes platform, which offers a very unique way of treating patients with advanced melanoma and advanced cervical cancer. The biotech made the case in that it holds the potential to possibly be superior over other currently available therapies for these patient populations.